urothelial carcinoma

Open Access
Onset and Outcomes of Immune-related Adverse Events in Genitourinary Cancer Treated With Immune Checkpoint Inhibitors
MINORU KATO, SHOMA YAMAMOTO, TAISUKE MATSUE, NAO YUKIMATSU, TAIYO OTOSHI, TAKESHI YAMASAKI, HIROYASU KANEDA, MASAFUMI KURAJOH, ASAHIRO ITO, NAOSHI ODAGIRI, AKINOBU NAKATA, AIKO KOBAYASHI, KATSUYUKI KURATSUKURI and JUNJI UCHIDA

In Vivo March 2026, 40 (2) 980-991; DOI: https://doi.org/10.21873/invivo.14254
Open Access
Outcomes of Enfortumab Vedotin Treatment in Patients Ineligible for the EV-301 Trial
KAZUTAKA NAKAMURA, YUKI KOBARI, YUDAI ISHIYAMA, HANAE KONDO, TORU INAKAWA, YUKI NEMOTO, HIRONORI FUKUDA, KAZUHIKO YOSHIDA, JUNPEI IIZUKA, HIROAKI SHIMMURA, HIROSHI KOBAYASHI, YASUNOBU HASHIMOTO, HIDEKI ISHIDA, TSUNENORI KONDO and TOSHIO TAKAGI

In Vivo September 2025, 39 (5) 2766-2776; DOI: https://doi.org/10.21873/invivo.14075
Open Access
Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience
AKINORI MINATO, YUI MIZUSHIMA, YOSHIHIRO SUGITA, TOMOHISA TAKABA, TAKUO MATSUKAWA, KAZUMASA JOJIMA, RIEKO KIMURO, KATSUYOSHI HIGASHIJIMA, YUJIRO NAGATA, IKKO TOMISAKI, EIJI KASHIWAGI and NAOHIRO FUJIMOTO

In Vivo July 2025, 39 (4) 2123-2132; DOI: https://doi.org/10.21873/invivo.14008
Open Access
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin
MAMORU HASHIMOTO, KEN FUKIAGE, KOSEI TANIGUCHI, TAKAFUMI MINAMI, TAKAFUMI YANAGISAWA, WATARU FUKUOKAYA, RYOICHI MAENOSONO, YUKI YOSHIKAWA, TAKUYA TSUJINO, MASANOBU SARUTA, KIYOSHI TAKAHARA, YOSUKE HIRASAWA, TAKESHI HASHIMOTO, YOSHIO OHNO, TAKAHIRO KIMURA, RYOICHI SHIROKI and KAZUTOSHI FUJITA; on behalf of ULTRA-J group

In Vivo May 2025, 39 (3) 1533-1539; DOI: https://doi.org/10.21873/invivo.13953
Open Access
Steroid Premedication Impact on Efficacy and Cutaneous Toxicity of Enfortumab Vedotin for Advanced Urothelial Carcinoma
NOBUKI FURUBAYASHI, MANABU MOCHIDA, ATSUHIRO KIJIMA, YUSHI FUJIMOTO, MOTONOBU NAKAMURA and TAKAHITO NEGISHI

In Vivo May 2025, 39 (3) 1607-1614; DOI: https://doi.org/10.21873/invivo.13961
Open Access
Outcomes of Avelumab Treatment in Advanced Urothelial Carcinoma According to Age, Performance Status, and Timing
NOBUKI FURUBAYASHI, MANABU MOCHIDA, ATSUHIRO KIJIMA, YUSHI FUJIMOTO, MOTONOBU NAKAMURA and TAKAHITO NEGISHI

In Vivo March 2025, 39 (2) 976-987; DOI: https://doi.org/10.21873/invivo.13903
Open Access
Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma
NOBUKI FURUBAYASHI, TAKAHITO NEGISHI, MANABU MOCHIDA, ATSUHIRO KIJIMA, HARUMICHI KATSUKI and MOTONOBU NAKAMURA

In Vivo January 2025, 39 (1) 411-418; DOI: https://doi.org/10.21873/invivo.13843
Open Access
C-reactive Protein Is a Prognostic Factor for Survival in Metastatic Upper Tract Urothelial Carcinoma Patients Receiving Pembrolizumab
HIROTAKA NAGASAKA, SHOTARO YAMAMOTO, ATSUTO SUZUKI, KIMITSUGU USUI, HIDEYUKI TERAO, NOBORU NAKAIGAWA and TAKESHI KISHIDA

In Vivo July 2024, 38 (4) 1823-1828; DOI: https://doi.org/10.21873/invivo.13634
Open Access
Optimal Number of Cycles of First-line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma
AKINORI MINATO, DAICHI OHNO, KAZUKI MUROOKA, YUTAKA OKUMURA, TOMOHISA TAKABA, KATSUYOSHI HIGASHIJIMA, YUJIRO NAGATA, IKKO TOMISAKI, KENICHI HARADA and NAOHIRO FUJIMOTO

In Vivo July 2024, 38 (4) 1927-1934; DOI: https://doi.org/10.21873/invivo.13648
Open Access
Efficacy of Platinum-based Chemotherapy in Patients With Metastatic Urothelial Carcinoma With Variant Histology
AKINORI MINATO, KAZUKI MUROOKA, YUTAKA OKUMURA, TOMOHISA TAKABA, KATSUYOSHI HIGASHIJIMA, YUJIRO NAGATA, IKKO TOMISAKI, KENICHI HARADA and NAOHIRO FUJIMOTO

In Vivo March 2024, 38 (2) 873-880; DOI: https://doi.org/10.21873/invivo.13513

Main menu

User menu

Search

urothelial carcinoma

Pages